FDA Boots 15 Forgotten Drugs from Approval List Cleanly
Published Date: 3/12/2026
Notice
Summary
The FDA is officially pulling the plug on 15 drug approvals because the companies, including Watson Laboratories and others, told the FDA they stopped selling these medicines. This change kicks in on April 13, 2026, but companies can apply again if they want. No money penalties here—just a cleanup to keep things current and clear!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Fifteen Generic Drug Approvals Withdrawn
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) for listed generic medicines (examples include cimetidine, fluoxetine HCl, famotidine, sotalol HCl, paclitaxel injectable, doxazosin mesylate, gabapentin, bisoprolol fumarate/hydrochlorothiazide, and vinorelbine tartrate) as of April 13, 2026. The applicants told FDA they stopped marketing these products, and products in inventory on April 13, 2026 may still be dispensed until the inventory is depleted or the product expires.
Manufacturers May Refile; No Penalty
The FDA says the withdrawals are "without prejudice to refiling," so applicants may submit new ANDAs again if they choose. The applicants waived their opportunity for a hearing, and the notice describes this action as a cleanup rather than a monetary penalty.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2026-04796, Privacy Act of 1974; Matching Program
The FCC and USAC are teaming up with HUD to double-check who qualifies for Lifeline and the Affordable Connectivity Program, which help low-income families get affordable internet and phone service. This new computer matching program starts April 13, 2026, runs for 18 months, and aims to keep benefits fair and accurate. If you’re part of these programs, this means better verification but no changes to your current support.
Next: 2026-04800, Self-Regulatory Organizations; CME Securities Clearing Inc.; Notice of Filing of Proposed Rule Change To Modify the CME Securities Clearing Inc. Amended and Restated By-Laws, Board of Directors Charter, Risk Management Committee Charter, Nominating Committee Charter, and Audit Committee Charter
CME Securities Clearing Inc. is updating its rules and committee guidelines to get ready for launching new clearing services. These changes affect the Board of Directors and key committees, making sure everything runs smoothly and safely. The updates don’t signal any immediate cost changes but set the stage for a strong, well-organized future starting soon.